US WorldMeds, LLC, and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE: BHC), today announced the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Bausch Health Companies (BHC) Reports Q2 Revenues of $2.125B; Boosts FY18 Adj. EBITDA Guidance, Offers FY18 Revenue OutlookAugust 7, 2018 7:23 AM US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg TabletsAugust 6, 2018 7:00 AM